Whether the job is waking the brain after a peaceful sleep, initiating gastric secretion when dinner is served or orchestrating the elements of inflammation after a mosquito bite, histamine has been a known biological messenger for decades (Green, 1964; Eichler and Farah, 1966) . At the end of the twentieth century, in the midst of the genomics and bioinformatics revolution, researchers in this field knew of the existence of only three histamine receptors (H 1 , H 2 , and H 3 ). But histamine receptors are catching up! Not only have multiple forms of the H 3 receptor recently been described but also a new histamine receptor, H 4 , has now been identified.
The presently-known histamine receptors (H 1 , H 2 , and H 3 ) are all G protein-coupled molecules and they transduce extracellular signals via Gq, Gs, and Gi/o, respectively (Hill et al., 1997; Lovenberg et al., 1999) . Not surprisingly, classic pharmacology studies (Ash and Schild, 1966; Black et al., 1972; Arrang et al., 1983) argued for their existence decades before they were cloned (Gantz et al., 1991; Yamashita et al., 1991; Lovenberg et al., 1999 ). Likewise, heterogeneity among H 3 receptors had long been suspected based on agonist kinetics (West et al., 1990) , radioligand binding characteristics (Cumming et al., 1991; Alves-Rodrigues et al., 1996) , peripheral versus central nervous system pharmacology Harper et al., 1999) , and other functional studies (Schlicker et al., 1992; Schworer et al., 1994) , but the absence of subtype-selective compounds prevented firm classification.
Although the H 1 and H 2 receptors were cloned nearly a decade ago (Gantz et al., 1991; Yamashita et al., 1991) , the H 3 receptor was not cloned until 1999 (Lovenberg et al., 1999) . However, this elucidation of the H 3 receptor structure in man and other species (Lovenberg et al., 1999 Tardivel-Lacombe et al., 2000; Drutel et al., 2001 ) quickly led to discoveries of the H 3 receptor subtypes and the closely related H 4 receptor, which are discussed presently. Recent molecular studies have shown that a single form of the H 3 gene can give rise to multiple mRNA isoforms, named H 3A, H 3B , and H 3C in the rat (Drutel et al., 2001), and H 3L and H 3S in the guinea pig . The variants all are known to differ in the structure of their third cytoplasmic loops, although the relevant splicing mechanisms remain uncertain Drutel et al., 2001) . Thus far, similar variants in human samples have not been identified (Liu et al., 2000) , although the existence of multiple, somewhat different H 3 isoforms in humans was reported recently (Wellendorf et al., 2000) . The H 3 receptor isoform that seems to be most predominant in human brain corresponds to the rat H 3A and the guinea pig H 3L . In the January 2001 issue of this journal, pharmacological differences in the H 3 receptor subtypes, as well as evidence for a differential distribution of the subtypes in rat brain, were presented (Drutel et al., 2001 ). Considering the current interest in the H 3 autoreceptor , the ability of the H 3 heteroreceptor to regulate the activity of many brain transmitters (Hill et al., 1997; Hough, 1999) and the potential for developing new H 3 pharmacotherapies [e.g., in attention deficit/hyperactivity disorder, Alzheimer's disease, obesity, and others (Leurs et al., 1998; Tedford, 1998) ], the characterization of the H 3 receptor subtypes is of considerable significance.
Phylogenetic and homology analysis (Lovenberg et al., 1999) of the H 3 receptor showed it to be surprisingly different from the previously cloned H 1 and H 2 receptors, a likely explanation for the delay in its discovery. Indeed, at the time of the H 3 receptor cloning, its homology to any other known G protein-coupled receptor was only 31% . Because of this, the search for new receptors in a family more closely related to the H 3 receptor seemed promising. As described in the accompanying articles (Liu et al., 2001; Nguyen et al., 2001; Zhu et al., 2001 ) and in other recent (Oda et al., 2000) and concurrent (Morse et al., 2001) articles, screening of libraries and public databases for H 3 -like fragments succeeded and led to the cloning and preliminary characterization of what is now referred to as the H 4 receptor. This receptor is a 390-amino-acid, 7-transmembrane G protein-coupled receptor, with a 37 to 43% homology to the H 3 (58% in transmembrane regions). All of the current studies report identical amino acid sequences for the receptor (Liu et al., 2001; Morse et al., 2001; Nguyen et al., 2001; Zhu et al., 2001) ; this sequence varies slightly from that of the original H 4 report (Oda et al., 2000) . The human H 3 and H 4 receptors possess very similar genomic structures; both have two introns and three exons (Liu et al., 2001; Zhu et al., 2001) , although the receptors are localized on different chromosomes (20 and 18, respectively). In addition, like the H 3 receptor, the H 4 receptor seems to couple to Gi/o [and possibly to other pathways (Oda et al., 2000) ], thereby inhibiting forskolin-activated cAMP formation (Zhu et al., 2001 ). Evidence for a plasma membrane localization and agonist-stimulated internalization of H 4 has also been presented (Nguyen et al., 2001) . Notably, the distribution of the H 4 receptor is quite different from that of the H 3 receptor. In contrast to a nearly exclusive brain localization for the H 3 receptor, the H 4 receptor shows highest levels in bone marrow and leukocytes (particularly eosinophils and neutrophils), with moderate levels in spleen and small intestine. Mast cells may also contain the H 4 receptor (Zhu et al., 2001) . Northern analyses and other preliminary expression studies reported the absence of the H 4 receptor in the central nervous system (Oda et al., 2000; Morse et al., 2001; Nguyen et al., 2001) . However, in situ hybridization studies in mouse (Zhu et al., 2001) and RNase protection assays in human samples (Liu et al., 2001 ) yielded evidence for a brain localization.
In general, the H 4 studies show excellent agreement on the preliminary pharmacology of the new receptor. Reported potencies of histaminergic compounds in competing against [ 3 H]histamine binding to the various H 4 clones are highly correlated across four laboratories (Fig. 1) . However, results with [
3 H]pyrilamine binding on another H 4 clone are discrepant (Fig. 1) . These results, along with the lack of activity of pyrilamine on the H 4 receptor reported by other labs (Table  1) , raise a question regarding the suitability of pyrilamine as radioligand for studying the H 4 receptor. Although the reasons for this discrepancy are not clear, it should be noted that [ 3 H]pyrilamine (also known as mepyramine) has been used as a radioligand for the H 1 receptor, but was later shown to also bind specifically to certain cytochrome isozymes, thus yielding false positives for the H 1 assay (Leurs et al., 1989; Liu et al., 1994) .
Given the structural similarities of the receptor, it is not surprising that the pharmacologies of the H 3 and H 4 receptors overlap (Table 1; Fig. 2 ). The high-affinity H 3 agonists also have H 4 agonist activity, but with a reduced potency. Most notable is (R)-␣-methylhistamine, which shows several hundred-fold weaker activity at H 4 versus H 3 receptors. Thioperamide, the prototypical H 3 antagonist, also has appreciable H 4 antagonist activity (Table 1; Fig. 2 ). Some data (Liu et al., 2001) even suggest that this drug may be an inverse agonist at H 4 receptors, similar to recent results showing this effect on H 3 receptors . Most of the results suggest that thioperamide has a 5-to 10-fold lower potency at the H 4 receptor than at the H 3 receptor (Table 1; Fig. 2) . The H 3 antagonists clobenpropit and burimamide also have a lower affinity for the H 4 receptor, but these compounds show partial agonist activity at the new receptor. Most promising for pharmaceutical development are data showing the existence of potent, non-imidazole H 3 antagonists (e.g., compound 17 in Table 1 and Fig. 2 ) that lack activity at the H 4 receptor ( Table 1) . Taken together, these results suggest that H 4 responses are activated by low doses of histamine, but not by (R)-␣-methylhistamine, and are blocked by large doses of thioperamide (an imidazole) but not by non-imidazole-containing H 3 antagonists. Although compounds capable of selectively acting at the new receptor have not yet been described, the atypical antipsychotic drug clozapine (discussed further below) shows moderate H 4 and no H 3 activity (Fig. 2) , and thus may be a lead in this direction.
The above characteristics suggest that the H 4 receptor has been with us longer than we realized. Raible et al. (1994) reported a histamine-activated increase in cytosolic calcium in human eosinophils; the effect was sensitive to thioperamide and partially mimicked by burimamide but not by low concentrations of (R)-␣-methylhistamine. Similarly, the histamine-induced inhibition of serotonin release in intestinal enterochromaffin cells resembles an H 4 response with respect to pharmacology and tissue expression (Schworer et al., 1994) . It is also likely that the "histamine uptake" discovered in bone marrow hematopoietic cells (Corbel et al., 1997) represents in-fact binding of [ 3 H]histamine and other ligands to the H 4 receptor, based on the pharmacology. In some of these studies, the potency of thioperamide can be difficult to interpret because of a large species difference (up to 10-fold) in the affinity of thioperamide for the human versus the rat H 3 receptor ; the difference is controlled by only two amino acid substitutions . There are other reported effects of thioperamide that are not reversed by H 3 agonists, and the H 4 receptor must now be considered in these cases. For example, thioperamide increases extracellular levels of both histamine and ␥-aminobutyric acid in brain, but only the former effect is reversed by H 3 agonists (Yamamoto et al., 1997) . Of course, thioperamide actions are not restricted to the H 3 and H 4 receptors; it has some affinity at other sites as well [e.g., 5-HT 3 ] and may even be found to have activity at additional, unknown histamine receptors. Although the new H 4 work accounts for the existence of some novel histamine receptors previously suggested to exist, it cannot account for others. For example, HTMT [6-[2-(4-imidazolyl)ethylamino]-N-(4-trifluoromethylphenyl)heptanecarboxamide], the histamine Table 1 Zhu et al. (2001) plotted against those from Morse et al. (2001) . Potency values agreed well across the H 4 clones when labeled histamine was used (P Ͻ 0.01), but not when labeled pyrilamine was used. The clones had identical H 4 sequences except for one (Oda et al., 2000) , which differed by three amino acids. Values plotted as 10,000 nM were reported to be inactive at that concentration.
derivative that suppresses lymphocyte function by a novel receptor (Khan et al., 1986) , is not active at the H 4 (Table 1) . Similarly, improgan, a cimetidine congener that induces analgesia by a mechanism distinct from known histamine receptors (Hough et al., 2000) , also had low affinity for the H 4 site ( Table 1) .
The newly discovered effects of clozapine on the H 4 receptor (Table 1, Fig. 2 ) add a new chapter to the longstanding relationship between psychosis, antipsychotic drugs, and brain histamine (Green et al., 1977; Raucher et al., 1977) . Chlorpromazine, the first neuroleptic, was developed from the early H 1 antagonists, and many neuroleptics have activity at both H 1 and H 2 receptors (Hough and Green, 1984) . Activity at the former is thought to contribute to the sedative profile of these drugs, and H 2 antagonists may be beneficial in treating psychosis (Rosse et al., 1996) . The atypical neuroleptic clozapine was reported to have moderate activity on the rat brain H 3 receptor (Rodrigues et al., 1995) , an effect confirmed on the rat (Kathmann et al., 1994) but not on the human receptor (Table 1) . Although the K i value for clozapine on the H 4 receptor is relatively high (500 -700 nM, Table  1 ), plasma and brain concentrations associated with clinical responses meet or exceed these values (Baldessarini and Frankenburg, 1991 ) Even more interesting is that clozapine seems to be an agonist at H 4 receptors (Oda et al., 2000; Liu et al., 2001 ). Although we do not yet know the consequences of H 4 receptor stimulation in the hippocampus (Zhu et al., 2001) or in eosinophils, it seems quite possible that patients taking clozapine are recipients of both actions. Whether this receptor participates in either the therapeutic or toxic effects of this drug is an intriguing question which remains to be answered; it is tempting to speculate that the eosinophilic a Guinea pig ileum (Hill et al., 1997) . b Guinea pig atrium (Hill et al., 1997 (Morse et al., 2001 ). g T. Lovenberg, unpublished observations. h Radioligand binding (Tran et al., 1978) . i Adenylate cyclase (Green et al., 1977) . j Bioassay (Ganellin, 1982) . k Bioassay EC 50 values (Hill et al., 1997) . l Highly selective H 3 agonists (Hill et al., 1997) . m Thioperamide has up to a 10-fold higher potency on the rat H 3 receptor . n Radioligand binding (Baldessarini and Frankenburg, 1991) . o L. Hough and J. P. Green, unpublished observations. p Clozapine has activity on the rat (Kathmann et al., 1994; Rodrigues et al., 1995) , but not the human H 3 receptor (Lovenberg et al., 1999) . q See Li et al. (1996) for improgan K d values.
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at ASPET Journals on August 15, 2017 molpharm.aspetjournals.org agranulocytosis, which often limits clozapine effectiveness, might be related to the H 4 receptor (Oda et al., 2000) . Much additional work on the H 4 system is needed. H 4 receptor subtypes may be found based on similarities to H 3 . The activities of the histamine metabolites need to be assessed on this receptor, because several of these metabolites have biological activity (Phillis et al., 1968; Thomas and Prell, 1995) , and histamine metabolism is highly regulated in some cases (Haddock et al., 1990) . Finally, H 4 -selective drugs will need to be developed that can further define the biological roles for this receptor and lead to unique pharmacotherapies. All indications suggest that many more receptors for histamine remain to be discovered.
